Association of Early Postinduction Adalimumab Exposure With Subsequent Clinical and Biomarker Remission in Children with Crohn’s Disease
- Resource Type
- Authors
- Amanda Ricciuto; Anne M. Griffiths; Firas Rinawi; Eileen Crowley; Karen Frost; Thomas D. Walters; Peter C Church
- Source
- Inflammatory Bowel Diseases. 27:1079-1087
- Subject
- 0301 basic medicine
medicine.medical_specialty
Gastroenterology
Likelihood ratios in diagnostic testing
03 medical and health sciences
0302 clinical medicine
Crohn Disease
Internal medicine
Adalimumab
Dose escalation
Humans
Immunology and Allergy
Medicine
Prospective Studies
Child
Crohn's disease
business.industry
Remission Induction
Area under the curve
medicine.disease
Clinical trial
Treatment Outcome
030104 developmental biology
Biomarker (medicine)
Tumor Necrosis Factor Inhibitors
030211 gastroenterology & hepatology
Calprotectin
business
Biomarkers
medicine.drug
- Language
- ISSN
- 1536-4844
1078-0998
Background Data on the association between early postinduction serum adalimumab (ADA) trough levels (TLs) and objective outcomes are scarce. The aim of this study was to investigate whether early ADA TLs at weeks 4 and 8 are associated with clinical and biomarker remission at week 24 in pediatric Crohn’s disease (CD). Methods Adalimumab TLs at weeks 4 and 8 were prospectively measured in anti-TNF-naïve children initiating treatment with ADA monotherapy for luminal inflammatory CD. The primary outcome was combined clinical and biomarker remission at week 24, defined as achieving steroid-free clinical remission (Pediatric CD activity index Results Among 65 patients, 39 (60%) achieved combined clinical/biomarker remission at week 24 without dose escalation. Adalimumab TLs at both weeks 4 and 8 were significantly higher in remitters vs nonremitters at week 24 (P Conclusion Greater early ADA exposure is associated with superior clinical/biomarker outcomes at week 24.